152 related articles for article (PubMed ID: 26305676)
21. Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.
Li C; Chen D; Luo M; Ge M; Zhu J
Biotechnol J; 2014 May; 9(5):652-63. PubMed ID: 24799381
[TBL] [Abstract][Full Text] [Related]
22. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
23. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth.
Shukla SK; Dasgupta A; Mehla K; Gunda V; Vernucci E; Souchek J; Goode G; King R; Mishra A; Rai I; Nagarajan S; Chaika NV; Yu F; Singh PK
Oncotarget; 2015 Dec; 6(38):41146-61. PubMed ID: 26510913
[TBL] [Abstract][Full Text] [Related]
24. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
25. Disruption of NF-κB1 prevents bone loss caused by mechanical unloading.
Nakamura H; Aoki K; Masuda W; Alles N; Nagano K; Fukushima H; Osawa K; Yasuda H; Nakamura I; Mikuni-Takagaki Y; Ohya K; Maki K; Jimi E
J Bone Miner Res; 2013 Jun; 28(6):1457-67. PubMed ID: 23322687
[TBL] [Abstract][Full Text] [Related]
26. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling.
Zhai Z; Qu X; Yan W; Li H; Liu G; Liu X; Tang T; Qin A; Dai K
Breast Cancer Res Treat; 2014 Feb; 144(1):33-45. PubMed ID: 24481680
[TBL] [Abstract][Full Text] [Related]
27. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
28. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
30. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B
Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
[TBL] [Abstract][Full Text] [Related]
31. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
32. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
33. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
34. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
35. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.
Huang C; Jiang T; Zhu L; Liu J; Cao J; Huang KJ; Qiu ZJ
Int J Oncol; 2011 Jun; 38(6):1637-44. PubMed ID: 21479358
[TBL] [Abstract][Full Text] [Related]
36. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
37. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
38. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.
Wang FS; Ko JY; Lin CL; Wu HL; Ke HJ; Tai PJ
Bone; 2007 Feb; 40(2):485-92. PubMed ID: 17055793
[TBL] [Abstract][Full Text] [Related]
39. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G
Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446
[TBL] [Abstract][Full Text] [Related]
40. Soybean extracts increase cell surface ZIP4 abundance and cellular zinc levels: a potential novel strategy to enhance zinc absorption by ZIP4 targeting.
Hashimoto A; Ohkura K; Takahashi M; Kizu K; Narita H; Enomoto S; Miyamae Y; Masuda S; Nagao M; Irie K; Ohigashi H; Andrews GK; Kambe T
Biochem J; 2015 Dec; 472(2):183-93. PubMed ID: 26385990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
